Penghui Wang

Penghui Wang is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative compounds that target various metabolic diseases. His work has the potential to impact the treatment of conditions related to sphingomyelin levels in the body.

Latest Patents

Wang holds a patent for a compound titled "2-alkyloxy benzene formyl arylamine compound and pharmaceutical use thereof." This patent describes the synthesis of 2-alkoxy benzene formyl arylamine compounds and their pharmaceutical salts. These compounds serve as sphingomyelin synthase (SMS) inhibitors, which can be utilized to treat diseases caused by the abnormal increase of sphingomyelin (SM). The pharmaceutical compositions derived from these compounds are designed to prevent and cure diseases such as atherosclerosis, fatty liver, obesity, type 2 diabetes, and other metabolic syndromes.

Career Highlights

Throughout his career, Penghui Wang has been associated with prominent institutions, including Fudan University and Beijing Supersonic Technology Co., Ltd. His work in these organizations has allowed him to advance his research and contribute to the scientific community.

Collaborations

Wang has collaborated with notable colleagues such as Deyong Ye and Yali Li. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Penghui Wang's contributions to pharmaceutical innovations highlight his role as a key inventor in the industry. His patented compounds offer promising solutions for treating serious health conditions related to sphingomyelin levels.

Profile summary based on public USPTO records.